Advertisement
Advertisement
LEXX
Lexaria Bioscience Corp. Common Stock
1.03
USDSponsored
+0.01
+0.98%
Apr 15, 15:58 UTC -4
Closed
After-Market
1.02
-0.01
-0.97%
LEXX Earnings Reports
Positive Surprise Ratio
LEXX beat 7 of 16 last estimates.
44%
Next Report
Date of Next Report
Jul 13, 2026
Estimate for Q3 26 (Revenue/ EPS)
$51.00K
/-$0.08
Implied change from Q2 26 (Revenue/ EPS)
+155.00%
/+33.33%
Implied change from Q3 25 (Revenue/ EPS)
-70.69%
/-61.90%
Lexaria Bioscience Corp. Common Stock earnings per share and revenue
On Apr 13, 2026, LEXX reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.09 USD, resulting in a 38.08% surprise. Revenue reached 20.00 thousand, compared to an expected 51.00 thousand, with a -60.78% difference. The market reacted with a +7.69% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 51.00 thousand USD, implying an increase of 33.33% EPS, and increase of 155.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
FAQ
What were Lexaria Bioscience Corp. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Lexaria Bioscience Corp. Common Stock reported EPS of -$0.06, beating estimates by 38.08%, and revenue of $20.00K, -60.78% below expectations.
How did the market react to Lexaria Bioscience Corp. Common Stock's Q2 2026 earnings?
The stock price moved up 7.69%, changed from $0.91 before the earnings release to $0.98 the day after.
When is Lexaria Bioscience Corp. Common Stock expected to report next?
The next earning report is scheduled for Jul 13, 2026.
What are the forecasts for Lexaria Bioscience Corp. Common Stock's next earnings report?
Based on 3
analysts, Lexaria Bioscience Corp. Common Stock is expected to report EPS of -$0.08 and revenue of $51.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement